Healthcare

The interest is understandable. Drug developers operate in a corner of the market where a single trial readout can reset the entire investment case, and that asymmetry is precisely what pulls in investors hunting for outsized outcomes. When sentiment toward biotech improves, the share …

Saluda Medical Inc. (ASX:SLD) shares climbed 14.63% to AUD 0.47 during the morning trading session on 30 June 2026 after the company announced that the U.S. Food and Drug Administration (FDA) had approved its CAP24 surgical paddle lead for commercial sale in the United …

• Mesoblast (ASX: MSB) advanced 5.44% to $1.99, riding a broad rotation into healthcare and growth on the ASX.

• Neuren Pharmaceuticals (ASX: NEU) soared 35.41% to $16.52, the single biggest gainer on the ASX for the session.

• Recce Pharmaceuticals (ASX: RCE) has raised $8 million in fresh capital to fund advancing clinical programs

• Monash IVF (ASX: MVF) is one of Australia’s most established fertility services providers, with a clinical network spanning multiple states and international markets.

• Neurizon Therapeutics (ASX: NUZ) has locked in a drug supply agreement to underpin its motor neurone disease clinical program